NewAmsterdam Pharma (NAMSW) furnishes updated corporate investor presentation

Rhea-AI Filing Summary

NewAmsterdam Pharma Company N.V. furnished a current report to let the market know it has posted an updated corporate investor presentation on its website as of September 2, 2025. The presentation, dated the same day, is attached as Exhibit 99.1 and provides investors with the latest corporate information in slide format. The company emphasizes that this material is furnished under Regulation FD, not filed, meaning it is not subject to certain securities law liabilities and is not automatically incorporated into any of its existing or future registration statements or Exchange Act filings unless expressly stated.

false000193625800-00000000001936258us-gaap:CommonStockMember2025-09-022025-09-0200019362582025-09-022025-09-020001936258us-gaap:WarrantMember2025-09-022025-09-02

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September, 2 2025

NewAmsterdam Pharma Company N.V.

(Exact name of Registrant as Specified in Its Charter)

The Netherlands			001-41562	N/A
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
Gooimeer 2-35
Naarden
The Netherlands				1411 DC
(Address of Principal Executive Offices)				(Zip Code)
			+31 (0) 35 206 2971
(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary shares, nominal value €0.12 per share		NAMS		The Nasdaq Stock Market LLC
Warrants to purchase ordinary shares		NAMSW		The Nasdaq Stock Market LLC

☐	Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
☐	If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

On September 2, 2025, NewAmsterdam Pharma Company N.V. (the Company) posted an updated corporate investor presentation on its website (https://www.newamsterdampharma.com). A copy of the corporate investor presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information contained on, or that can be accessed from, the Company’s website is not incorporated into, and does not constitute a part of, this Current Report on Form 8-K.

The information contained in this Item 7.01, including Exhibit 99.1, is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liability of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the Securities Act). The information contained in this Item 7.01, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		NewAmsterdam Pharma Company N.V. Corporate Presentation, dated September 2, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			NewAmsterdam Pharma Company N.V.
Date:	September 2, 2025	By:	/s/ Michael Davidson
		Name:	Michael Davidson, M.D.
		Title:	Chief Executive Officer

FAQ

What did NewAmsterdam Pharma Company N.V. (NAMSW) disclose in this 8-K?

NewAmsterdam Pharma Company N.V. reported that it posted an updated corporate investor presentation on its website on September 2, 2025, and furnished that presentation as Exhibit 99.1.

Where can investors find NewAmsterdam Pharma Company N.V.’s updated corporate presentation?

The presentation is available on the company’s website at https://www.newamsterdampharma.com and is also included as Exhibit 99.1 to this report.

How is the NewAmsterdam Pharma (NAMSW) investor presentation treated under securities laws?

The information in Item 7.01 and Exhibit 99.1 is being furnished, not filed, so it is not subject to Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act.

Is the NewAmsterdam Pharma website information part of this 8-K filing?

The company states that information contained on, or accessed from, its website does not constitute a part of this report.

Can the NewAmsterdam Pharma investor presentation be incorporated into other SEC filings?

The company notes that the information in Item 7.01 and Exhibit 99.1 will not be incorporated by reference into any registration statement or other document unless expressly stated in such filing.

Who signed the NewAmsterdam Pharma (NAMSW) 8-K related to the investor presentation?

The report was signed on behalf of NewAmsterdam Pharma Company N.V. by Michael Davidson, M.D., the company’s Chief Executive Officer, dated September 2, 2025.